




The relative strengths and weaknesses of Matinas Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas Biopharma Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 51% points. The greatest weakness of Matinas Biopharma Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 219%, being 33% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	7,964
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	2,225
Liabilities, Non-Current	0
Other Assets	3,553
Other Compr. Net Income	0
Other Expenses	-357
Other Liabilities	1,517
Other Net Income	659
Other Revenues	150
Property and Equipment	1,570
Research and Development	9,010
Selling, General and Administrative Expense	7,642

Output Variable	Value in 1000 USD
Assets	14,424
Liabilities	3,742
Expenses	16,295
Revenues	150
Stockholders Equity	10,682
Net Income	-15,486
Comprehensive Net Income	-15,486
BaseVar	17,635
ECR before LimitedLiability	86%
Economic Capital Ratio	219%